In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by Merck. Ivonescimab reduced risk of tumour progression by 49%.
In FY 2025-26, AoN for 55 proposals amounting to Rs 6.73 lakh cr has been accorded by DAC. Both the quantum of AoN given and capital contracts signed, so far, have been the highest in any FY.
COMMENTS